423 related articles for article (PubMed ID: 11792343)
1. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
[TBL] [Abstract][Full Text] [Related]
3. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
[TBL] [Abstract][Full Text] [Related]
4. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
[TBL] [Abstract][Full Text] [Related]
6. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
[TBL] [Abstract][Full Text] [Related]
9. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Day R; Morrison B; Luza A; Castaneda O; Strusberg A; Nahir M; Helgetveit KB; Kress B; Daniels B; Bolognese J; Krupa D; Seidenberg B; Ehrich E
Arch Intern Med; 2000 Jun; 160(12):1781-7. PubMed ID: 10871971
[TBL] [Abstract][Full Text] [Related]
11. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
Saag K; van der Heijde D; Fisher C; Samara A; DeTora L; Bolognese J; Sperling R; Daniels B
Arch Fam Med; 2000; 9(10):1124-34. PubMed ID: 11115219
[TBL] [Abstract][Full Text] [Related]
12. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
White WB; Strand V; Roberts R; Whelton A
Am J Ther; 2004; 11(4):244-50. PubMed ID: 15266215
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Curtis SP; Ko AT; Bolognese JA; Cavanaugh PF; Reicin AS
Curr Med Res Opin; 2006 Dec; 22(12):2365-74. PubMed ID: 17265571
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.
Morgan GJ; Poland M; DeLapp RE
Am J Med; 1993 Aug; 95(2A):19S-27S. PubMed ID: 8356998
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis.
Pellissier JM; Straus WL; Watson DJ; Kong SX; Harper SE
Clin Ther; 2001 Jul; 23(7):1061-79. PubMed ID: 11519771
[TBL] [Abstract][Full Text] [Related]
19. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
20. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Matheson AJ; Figgitt DP
Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
